DPYD genotyping panels: Impact of population diversity.
作者信息
Suarez-Kurtz Guilherme
机构信息
Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
出版信息
Clin Transl Sci. 2024 Apr;17(4):e13805. doi: 10.1111/cts.13805.
Abstract
摘要
相似文献
1
DPYD genotyping panels: Impact of population diversity.
Clin Transl Sci. 2024 Apr;17(4):e13805. doi: 10.1111/cts.13805.
2
Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping.
Oncologist. 2022 May 6;27(5):e420-e421. doi: 10.1093/oncolo/oyac057.
3
Implementation of DPYD Genotyping in Admixed American Populations: Brazil as a Model Case.
Clin Pharmacol Ther. 2023 Jul;114(1):23-24. doi: 10.1002/cpt.2921. Epub 2023 May 10.
4
Universal Pretreatment Genotyping in Fluoropyrimidine Candidates: Still Controversial but With Clear Instructions for Practitioners, at Last!
JCO Oncol Pract. 2020 Dec;16(12):801-802. doi: 10.1200/OP.20.00903.
5
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Pharmacogenomics. 2016 May;17(7):721-9. doi: 10.2217/pgs-2016-0013. Epub 2016 May 16.
6
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Breast Cancer Res Treat. 2019 Jun;175(2):511-517. doi: 10.1007/s10549-019-05144-9. Epub 2019 Feb 12.
7
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):89-92.
8
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Eur J Cancer. 2016 Feb;54:40-48. doi: 10.1016/j.ejca.2015.11.008. Epub 2015 Dec 21.
9
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Eur J Hum Genet. 2020 Apr;28(4):508-517. doi: 10.1038/s41431-019-0540-0. Epub 2019 Nov 19.
10
Testing: Time to Put Patient Safety First.
J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23.
本文引用的文献
1
Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.
Clin Transl Sci. 2024 Jan;17(1):e13699. doi: 10.1111/cts.13699.
2
Implementation of DPYD Genotyping in Admixed American Populations: Brazil as a Model Case.
Clin Pharmacol Ther. 2023 Jul;114(1):23-24. doi: 10.1002/cpt.2921. Epub 2023 May 10.
3
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
Clin Pharmacol Ther. 2022 Oct;112(4):791-802. doi: 10.1002/cpt.2667. Epub 2022 Jun 12.
4
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.
Zotero 插件